Evidence map›Paper›PMID 31809211›Full record

ArticleAmerican journal of physiology. Heart and circulatory physiology2020

Antenatal sildenafil citrate treatment increases offspring blood pressure in the placental-specific

L J Renshall, E C Cottrell, E Cowley, C P Sibley, P N Baker, E B Thorstensen, S L Greenwood, M Wareing, M R Dilworth

Open access · hybridAbstract read
In one paragraph

Article in American journal of physiology. Heart and circulatory physiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Sildenafil during the 2nd and 3rd Trimester of Pregnancy: Trials and Tribulations.International journal of environmental research and public health · 2022
    Review
  2. Article
  3. Article
  4. Article
  5. Preeclampsia beyond pregnancy: long-term consequences for mother and child.American journal of physiology. Renal physiology · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

L J RenshallMaternal and Fetal Health Research Centre, Division of Developmental Biology and Medicine, School of Medicine, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom.ORCID 0000-0002-2491-8014
E C CottrellMaternal and Fetal Health Research Centre, Division of Developmental Biology and Medicine, School of Medicine, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom.
E CowleyMaternal and Fetal Health Research Centre, Division of Developmental Biology and Medicine, School of Medicine, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom.
C P SibleyMaternal and Fetal Health Research Centre, Division of Developmental Biology and Medicine, School of Medicine, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom.
P N BakerLiggins Institute, The University of Auckland, Grafton, Auckland, New Zealand.
E B ThorstensenLiggins Institute, The University of Auckland, Grafton, Auckland, New Zealand.
S L GreenwoodMaternal and Fetal Health Research Centre, Division of Developmental Biology and Medicine, School of Medicine, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom.
M WareingMaternal and Fetal Health Research Centre, Division of Developmental Biology and Medicine, School of Medicine, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom.
M R DilworthMaternal and Fetal Health Research Centre, Division of Developmental Biology and Medicine, School of Medicine, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom.
Manchester Academic Health Science Centre · GBUniversity of Auckland · NZUniversity of Leicester · GB

Funding

Medical Research Council G0802770Medical Research Council MR/K024442/1
6 · The paper itself

Abstract

Fetal growth restriction (FGR), where a fetus fails to reach its genetic growth potential, affects up to 8% of pregnancies and is a major risk factor for stillbirth and adulthood morbidity. There are currently no treatments for FGR, but candidate therapies include the phosphodiesterase-5 inhibitor sildenafil citrate (SC). Randomized clinical trials in women demonstrated no effect of SC on fetal growth in cases of severe early onset FGR; however, long-term health outcomes on the offspring are unknown. This study aimed to assess the effect of antenatal SC treatment on metabolic and cardiovascular health in offspring by assessing postnatal weight gain, glucose tolerance, systolic blood pressure, and resistance artery function in a mouse model of FGR, the placental-specific insulin-like growth factor 2 (PO) knockout mouse. SC was administered subcutaneously (10 mg/kg) daily from embryonic day (E)12.5. Antenatal SC treatment did not alter fetal weight or viability but increased postnatal weight gain in wild-type (WT) female offspring (

Indexed as

AnimalsBirth WeightBlood PressureFemaleFetal Growth RetardationGlucose Tolerance TestInsulin-Like Growth Factor IIMiceMice, Inbred C57BLMice, KnockoutPregnancyPrenatal Exposure Delayed EffectsSildenafil CitrateSplanchnic CirculationVascular ResistanceVasodilator AgentsIGF2 protein, mouseInsulin-Like Growth Factor IISildenafil CitrateVasodilator Agentsblood pressurefetal growth restrictionoffspringsildenafil citrate

Identifiers

PMID31809211
PMCPMC7052623
OpenAlexW2991817744

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.